Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating idiopathic pulmonary fibrosis and application of such pharmaceutical composition

A technology for pulmonary fibrosis and a composition is applied in the field of pharmaceutical compositions for the treatment of idiopathic pulmonary fibrosis, which can solve the problems of large toxic and side effects, poor treatment effect, etc., and achieves no toxic and side effects, wide application value, and difficulty in recurrence. Effect

Inactive Publication Date: 2017-05-10
ZHENGZHOU ZHANGMENG NETWORK TECH CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the above-mentioned drugs for the treatment of idiopathic pulmonary fibrosis have disadvantages such as poor therapeutic effect and relatively large toxic and side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating idiopathic pulmonary fibrosis and application of such pharmaceutical composition
  • Pharmaceutical composition for treating idiopathic pulmonary fibrosis and application of such pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] In the embodiment of the present invention, a pharmaceutical composition for treating idiopathic pulmonary fibrosis is composed of nafamostat and artesunate, wherein the mass ratio of nafamostat and artesunate is 1.6:1.

Embodiment 2

[0017] In the embodiment of the present invention, a pharmaceutical composition for treating idiopathic pulmonary fibrosis is composed of nafamostat and artesunate, wherein the mass ratio of nafamostat and artesunate is 2.4:1.

Embodiment 3

[0019] In the embodiment of the present invention, a pharmaceutical composition for treating idiopathic pulmonary fibrosis is composed of nafamostat and artesunate, wherein the mass ratio of nafamostat and artesunate is 1.8:1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating idiopathic pulmonary fibrosis and application of such pharmaceutical composition. The pharmaceutical composition is prepared by compositing nafamostat and artesunate in a mass ratio of 1.6-2.4:1. Administration dosage for adults is 0.45-0.50mg / kg / day when the pharmaceutical composition is used for treating idiopathic pulmonary fibrosis. Clinical experiments show that the pharmaceutical composition is remarkably effective in treatment of acute idiopathic pulmonary fibrosis, subacute idiopathic pulmonary fibrosis, chronic idiopathic pulmonary fibrosis and acute onset of chronic idiopathic pulmonary fibrosis, reaches the total effective rate of 92-96%, and is capable of avoiding proneness to relapse and free of toxic or side effect, thereby being high in application value.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to a medicine composition for treating idiopathic pulmonary fibrosis and its application. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) is one of the chronic interstitial lung diseases of unknown etiology, and it is also a chronic inflammatory lung disease characterized by pathological changes of common interstitial pneumonia. The pathogenesis is still not very clear. In 2000, the American Thoracic Society and the European Respiratory Society jointly issued an international joint statement to clearly define idiopathic pulmonary fibrosis, believing that idiopathic pulmonary fibrosis is an independent disease, and its pathomorphological manifestations are Usual interstitial pneumonia (UIP) is different from other idiopathic interstitial pneumonias, such as desquamative interstitial pneumonia (DIP), acute interstitial pneumonia (AIP), nonspecific interstitial pne...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/357A61K31/245A61P11/00
CPCA61K31/357A61K31/245
Inventor 不公告发明人
Owner ZHENGZHOU ZHANGMENG NETWORK TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com